On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.

oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.

Burning Mouth Syndrome

Oral Mucosa Disease

1:Control group Specific medicines and usage, course of treatment are as follows: oryzanol + vitamin B2 (riboflavin) + vitamin E, oryzanol tablets, oral, 10 mg/time, 3 times/day; vitamin B2 tablets, oral, 10 mg/time, 3 times/day; vitamin E pills, oral, 100 mg/time, 1 time/day, 1 months as a course of treatment.
2.Therapeutic regimen of experimental group On the basis of classical "Gu-Nucleus-E" triple drug therapy, the experimental group was treated with head yuanshi dian therapy twice a day for 1 months as a course of treatment.

oryzanol + vitamin B2 (riboflavin) + vitamin E

Department of Oral Medicine, the Second Affiliated Hospital, School of Medicine Zhejiang University

Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Head Yuanshi Dian Therapy in the Treatment of Burning Mouth Syndrome: a Randomized Controlled Trial

The basic method is to use a swimming scale about 10 cm long, with 10 scales on one side, and the two ends are "0" and "10" ends respectively. 0 indicates no pain and 10 points represents the most severe pain that is unbearable.

Second Affiliated Hospital, School of Medicine, Zhejiang University

Zhejiang Provincial Hospital of TCM

Stomatological Hospital of Guiyang

1:1 randomized controlled clinical trial were used. Random numbers generated by SPSS21.0 will be placed in sequentially coded, sealed, opaque envelopes. When the qualifications of the subjects were determined by the researchers, the envelopes were opened sequentially and the subjects were assigned to groups. The odd number represented the experimental group and the even number represented the control group.

Each of the three centers has a researcher responsible for the treatment and interpretation of the subjects. The head of the research center trained the researcher to unify the standards. Three researchers were not involved in the evaluation of efficacy. Another researcher was responsible for recording pain and emotional nature and degree score, pain index, pain multi-dimensional characteristics score, depression index, Pittsburgh sleep quality index, Kupperman menopause score, dry mouth subjective symptoms questionnaire, saliva flow, and recording laboratory results, and collecting records. Data, analysis of efficacy, the researchers do not know the specific grouping, in order to minimize the subjective impact of the researchers on the test results.

Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.

Vitamin coenzyme Q10, magnesium, riboflavin and omega-3-fatty acid combination.

Concussion

Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids

Experimental: Vitamin Mixture

Placebo

Vitamin Therapy in Concussion Management: A Randomized Control Trial

Thomas Jefferson University

Rothman Institute Orthopaedics

Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis.

Migraine Prophylaxis

Histamine Dihydrochloride

Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

Phase II Study to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

Mean change from baseline in monthly migraine days [time frame: baseline and average over Weeks 3-22].

Mean change from baseline in monthly migraine days by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].

Mean Change from Baseline in Monthly Migraine Index (MMI) [ Time Frame: baseline and average over observation period (Weeks 3-22).
Monthly Migraine Index (MMI):
Migraine headaches are assigned a number based on the peak intensity of that migraine headache:
1 for a mild migraine headache
2 for a moderate migraine headache
3 for a severe migraine headache.
The MMI is calculated as follows:
MMI= Sum of [(Migraine Peak Intensity Level (1-3)) x (Migraine Duration (hours))] / (Distinct Number of Migraine Headaches for that 4 week period)
Sample Calculation:
The patient experiences 3 migraine headaches (M1, M2, and M3) in 4 weeks . M1: Intensity Level 3, Duration is 7 hrs M2: Intensity Level 2, Duration 3 hrs M3: Intensity Level 3, Duration 15 hrs MMI= (3x7 + 2x3 + 3x15) / 3 = 24

Mean change from baseline in monthly number of migraines [time frame: baseline and over Weeks 3-22].

Mean change from baseline in monthly number of migraines by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].

riboflavin/cefalea

Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Vitamin Therapy in Concussion Management: A Randomized Control Trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis

Il database di erbe medicinali più completo supportato dalla scienza